Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 5

Sponsor Class

OTHER 9INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 3Tumor-Agnostic 2CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 52Lung Neoplasms 11Breast Neoplasms 11Head and Neck Neoplasms 8Neoplasms 5Neoplasm Metastasis 4NSCLC 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Colorectal Neoplasms 3Carcinoma 3Brain Neoplasms 3Respiratory Tract Diseases 2Neoplasms, Squamous Cell 2Carcinoma, Squamous Cell 2Adenocarcinoma of Lung 2Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC 1Small Cell Lung Carcinoma 1Respiratory Tract Neoplasms 1Pancreatic Neoplasms 1Non-Metastatic Prostate Cancer 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma 1Lung Diseases 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × Gefitinib × Clear all
NCT03653546 2025-09-10

BM

Alpha Biopharma (Jiangsu) Co., Ltd.

Phase 2/3 Completed
492 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT01039948 2015-04-08

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

AVEO Pharmaceuticals, Inc.

Phase 1/2 Completed
203 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT00034879 2013-01-04

Iressa Expanded Access Program (EAP)

AstraZeneca

Phase 3 Completed
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT00127829 2009-04-23

AGUS

AstraZeneca

Phase 1 Completed
66 enrolled
Tumor-Agnostic

Neoplasms

NCT00635973 2009-04-22

Open-Label Extension of Other SZ1839 (Iressa) Trials

AstraZeneca

Phase 3 Completed
100 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡